Robert P. Ryan
Vorstandsvorsitzender bei Innova Therapeutics, Inc.
Profil
Robert P.
Ryan was the founder of Scioderm, Inc. (founded in 2012) where he held the title of President & Chief Executive Officer from 2013 to 2014.
He is currently the President & Chief Executive Officer at Innova Therapeutics, Inc. (since 2016), Chairman at viDA Therapeutics, Inc. (since 2016), Director at Dystrophic Epidermolysis Bullosa Rsch Assoc of America, Inc. (since 2013), and Director at Aegle Therapeutics Corp.
(current job).
Dr. Ryan's former positions include Non-Executive Director at Dominion Minerals Ltd.
(2016-2018), Director at Renovion, Inc., Principal at Bristol Myers Squibb Co., Principal at Pfizer Inc., VP-Regulatory Affairs & Pharmacovigilance at AtheroGenics, Inc., Chief Regulatory Officer at Quintiles, Inc. (California), Principal at Hoffmann-La Roche, Inc., VP-Regulatory Strategy, Consulting & Submissions at Syneos Health NC LLC, and Principal at UCB, Inc. Dr. Ryan's education includes a graduate degree from North Dakota State University and a doctorate degree from The University of North Carolina at Charlotte.
Aktive Positionen von Robert P. Ryan
| Unternehmen | Position | Beginn |
|---|---|---|
| Dystrophic Epidermolysis Bullosa Rsch Assoc of America, Inc. | Direktor/Vorstandsmitglied | 21.10.2013 |
viDA Therapeutics, Inc.
 viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | Vorsitzender | - |
Innova Therapeutics, Inc.
 Innova Therapeutics, Inc. BiotechnologyHealth Technology Innova Therapeutics, Inc. develops drug candidates for rare and orphan diseases. The private company is based in Palo Alto. Robert P. Ryan has been the CEO of the American company since 2016. | Vorstandsvorsitzender | 01.01.2016 |
Aegle Therapeutics Corp.
 Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Robert P. Ryan
| Unternehmen | Position | Ende |
|---|---|---|
| DOMINION MINERALS LIMITED | Direktor/Vorstandsmitglied | 11.12.2018 |
Renovion, Inc.
 Renovion, Inc. Pharmaceuticals: MajorHealth Technology Renovion, Inc. develops therapy for chronic inflammatory airway diseases. It offers Arina-1, a nebulized therapy focused on chronic inflammatory airways diseases that is being evaluated as a twice daily nebulized therapy. The company was founded in 2013 and is headquartered in Chapel Hill, NC. | Direktor/Vorstandsmitglied | - |
UCB, Inc.
 UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Corporate Officer/Principal | - |
| PFIZER, INC. | Corporate Officer/Principal | - |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Corporate Officer/Principal | - |
Ausbildung von Robert P. Ryan
| The University of North Carolina at Charlotte | Doctorate Degree |
| North Dakota State University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| PFIZER, INC. | Health Technology |
| DOMINION MINERALS LIMITED | Non-Energy Minerals |
| Private Unternehmen | 11 |
|---|---|
Syneos Health NC LLC
 Syneos Health NC LLC Miscellaneous Commercial ServicesCommercial Services Syneos Health LLC operates therapeutically focused global contract research organization. It provides pharma and biotech services. The firm specializes in the hematology, immunology and inflammation infectious diseases, oncology, ophthalmology, cardiovascular, CNS analgesia, CNS neurology, CNS psychiatry, endocrinology, and gastroenterology and hepatology. The company was founded by Kenneth A. Selzer in 1985 and is headquartered in Raleigh, NC. | Commercial Services |
Scioderm, Inc.
 Scioderm, Inc. BiotechnologyHealth Technology Scioderm, Inc. engages in the development of innovative therapies for areas of high unmet need, including orphan products. The company was founded by Robert Ryan and Robert John Coull in 2012 and is headquartered in Durham, NC. | Health Technology |
Quintiles, Inc. (California)
 Quintiles, Inc. (California) Medical/Nursing ServicesHealth Services Quintiles, Inc. provides therapeutic services. It offers medical services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. The company was founded in 1982 and is headquartered in San Francisco, CA. | Health Services |
| Dystrophic Epidermolysis Bullosa Rsch Assoc of America, Inc. | |
AtheroGenics, Inc.
 AtheroGenics, Inc. Pharmaceuticals: MajorHealth Technology AtheroGenics is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis. | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Finance |
viDA Therapeutics, Inc.
viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | Health Technology |
Innova Therapeutics, Inc.
Innova Therapeutics, Inc. BiotechnologyHealth Technology Innova Therapeutics, Inc. develops drug candidates for rare and orphan diseases. The private company is based in Palo Alto. Robert P. Ryan has been the CEO of the American company since 2016. | Health Technology |
Renovion, Inc.
Renovion, Inc. Pharmaceuticals: MajorHealth Technology Renovion, Inc. develops therapy for chronic inflammatory airway diseases. It offers Arina-1, a nebulized therapy focused on chronic inflammatory airways diseases that is being evaluated as a twice daily nebulized therapy. The company was founded in 2013 and is headquartered in Chapel Hill, NC. | Health Technology |
Aegle Therapeutics Corp.
Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | Health Technology |
